# P 1-76

# Correlation with cognitive function and chemotherapy in breast cancer: preliminary study

Na Ri Yun<sup>1\*</sup>, Ji Hee Kim<sup>1†</sup>

Wonkwang University School of Medicine, Department of Rehabilitation Medicine<sup>1</sup>

#### Objectives

To investigate the effect of chemotherapy on cognitive function, cardiorespiratory fitness and physical activity in breast cancer patient.

#### Methods

From June 2017 to April 2018, patients between the ages of 40-70 who underwent surgery due to breast cancer in the department of the breast and thyroid surgery were enrolled. A total 10 patients were recruited and divided into two groups. Patients treated with chemotherapy are chemotherapy group (n=5), and patients who did not receive chemotherapy are non-chemotherapy group (n=5). Age, types of breast cancer surgery, history of chemotherapy and radiotherapy, education level, Korean version of the Mini-Mental State Exam (K-MMSE), Beck depression inventory (BDI) were collected as demographic data. In addition, we performed the Korean version of Montreal cognitive assessment (MOCA-K), Computerized Neuro-cognitive Function Test (CNT) for cognitive function evaluation and evaluated the International Physical Activity Questionnaire (IPAQ) to measure physical activity level. We also performed cardiopulmonary exercise test using modified Bruce protocol to evaluate cardiorespiratory fitness. All outcomes were measured after surgery (T0, baseline) and immediately after the anti-cancer therapy (T1).

## Results

Among the chemotherapy group, the mean age was  $56.2 \pm 8.1$ , and  $48.8 \pm 4.3$  in the nonchemotherapy group. In chemotherapy group, breast cancer stage 2 and 3 were more frequent, and mastectomy was performed more frequently. Education level, K-MMSE, BDI scores did not showed significant differences between two groups (Table 1). No significant differences were found between two groups in the cognitive function outcomes at T0. There was also no significant change in cognitive function outcomes between T0 and T1 in both groups when compared within each group. In IPAQ, there was no significant difference between the two groups, but the ratio of Category 2 at T1 was increased in both groups (Table 2). Similarly, there was no significant difference between the two groups in the cardiorespiratory fitness parameters at T0. However, anaerobic threshold (AT) was significantly lower in the chemotherapy group than in the nonchemotherapy group at T1 (18.38 and 24.66 respectively, p<0.05) (Table 3).

## Conclusions

Chemotherapy did not significantly affect cognitive function, cardiorespiratory fitness, and physical activity at the time immediately after chemotherapy in breast cancer

patients. However, further evaluation of the effect of chemotherapy on these parameters over time will be needed in future through a long-term follow up evaluation.

Parameters	Chemotherapy group (n=5)	Non- chemotherapy group (n=5)	<i>p</i> -value	
Age (year)	56.2 ± 8.1	48.8 ± 4.3	0.095	
Breast cancer stage				
I	0 (0)	5 (100)	0.000*	
п	3 (60)	0 (0)	0.008	
ш	2 (40)	0 (0)		
Surgery type				
Breast-conserving surgery+radiotherapy	1 (20)	5 (100)	0.048*	
Mastectomy	4 (80)	0 (0)		
Neoadjuvant chemotherapy only	0 (0)	0 (0)		
Chemotherapy				
TC	2 (40)			
AC	0 (0)	N/A		
TC+AC	3 (60)			
Radiotherapy	3 (60)	5 (100)	0.444	
Education level				
Elementary school	1 (20)	0 (0)		
Middle school	0 (0)	3 (60)	0.357	
High school	2 (40)	1 (20)		
University	2 (40)	1 (20)		
K-MMSE	28.0 ± 1.2	28.0 ± 0.8	0.421	
BDI	11.4 ± 5.3	13.4 ± 10.1	0.841	

Table 1. Baseline characteristics of the subjects.

Values are presented as mean ± standard deviation or number (%).

TC, Doxitaxel, cyclophosphamide; AC, Doxorubicin, cyclophosphamide; K-MMSE, Korean version of the Mini-Mental State Exam; BDI, Beck Depression Inventory.

\*p<0.05

Variables	Group	Т	0	I	1	<i>p</i> -value	
K-MMSE	Chemotherapy	28.00	± 1.22	28.4	± 1.1	0.210	
	Non-chemotherapy	28.80	± 0.84	29.2	± 0.8	0.510	
MOCA-K	Chemotherapy	25.60	± 2.97	26.8	± 2.4	0.941	
	Non-chemotherapy	25.80	± 2.77	27.2	± 0.4	0.841	
CNT-D	Chemotherapy	45.90 ±	18.70	46.7	± 18.6	4 000	
	Non-chemotherapy	47.30 ±	18.09	47.7	± 17.5	1.000	
CNT-V	Chemotherapy	37.50	± 6.89	40.3	± 6.7	0.548	
	Non-chemotherapy	44.90	± 5.99	42.6	± 7.8		
CNT-T	Chemotherapy	39.00	± 8.85	42.1	± 10.4	0.690	
	Non-chemotherapy	39.60	± 8.60	40.4	± 8.1		
CNT-W	Chemotherapy	36.88	± 7.61	36.7	± 6.5	0.690	
	Non-chemotherapy	40.04 ±	10.75	40.0	± 9.9		
BDI	Chemotherapy	11.40	± 5.32	8.8	± 4.8	0.095	
	Non-chemotherapy	13.40 ±	10.14	13.4	± 2.5		
IPAQ	Chemotherapy	481.80 ± 336.21 431.80 ± 316.72		863.00 ± 470.40 647.70 ± 505.34		0.310	
(Continuous score)	Non-chemotherapy						
IPAQ	Chamatharany	C1	3 (60)	C1	2 (40)		
	Chemotherapy	C2	2 (40)	C2	3 (60)	1.000	
(Categorical score)	Non chamatharassi	C1	4 (80)	C1	3 (60)	1.000	
	Non-chemotherapy	C2	1 (20)	C2	2 (40)		

Table 2. Comparison of cognitive function, physical activity between two groups at baseline, post anti-cancer therapy

Values are presented as mean ± standard deviation or number (%).

K-MMSE, Korean version of the Mini-Mental State Exam; MOCA-K, Korean version of Montreal cognitive assessment; CNT-D, Computerized Neuro-cognitive Function Test-Digit span; CNT-V, Computerized Neuro-cognitive Function Test-Visual span; CNT-T, Computerized Neuro-cognitive Function Test-Trail making; CNT-W, Computerized Neuro-cognitive Function Test-Word color test; BDI, Beck Depression Inventory; IPAQ, International Physical Activity Questionnaire; C1, Category 1; C2, Category 2.

\**p*<0.05

Variables	Group	то	T1	<i>p</i> -value	
VO2max	Chemotherapy	22.36 ± 4.55	21.54 ± 2.06	0.222	
(ml/kg/min)	Non-chemotherapy	27.80 ± 2.96	26.98 ± 5.50		
METs	Chemotherapy	6.40 ± 1.32	6.14 ± 0.59	0.222	
	Non-chemotherapy	7.94 ± 0.85	7.70 ± 1.58	0.222	
RER	Chemotherapy	1.35 ± 0.17	1.37 ± 0.14	0.151	
	Non-chemotherapy	1.33 ± 0.13	1.24 ± 0.15	0.151	
VE <sub>max</sub>	Chemotherapy	52.51 ± 11.88	48.50 ± 7.02	0.421	
(L/min)	Non-chemotherapy	49.74 ± 7.90	43.32 ± 8.93		
AT	Chemotherapy	18.82 ± 2.98	18.38 ± 2.91	0.032*	
(ml/kg/min)	Non-chemotherapy	23.88 ± 4.85	24.66 ± 4.31		

Table 3. Comparison of cardiorespiratory fitness between the two groups at baseline, post anti-cancer therapy

VO2max, maximal oxygen consumption; METs, Metabolic equivalent tasks; RER, Respiratory <sup>b</sup> exchange ratio; VE<sub>max</sub> Maximal pulmonary Ventilation; AT, Anaerobic Threshold.

\**p*<0.05